Bülent KARABULUT, Veliddin Canfeza SEZGİN, Ulus Ali ŞANLI, Rüçhan USLU, Erdem GÖKER, Necmettin ÖZDEMİR, Selahattin SANAL

Meme kanserinde C-ERBB-2 ekspresyonu ile diğer prognostik faktörler arasında ilişki var mı?

C-erbB-2 insan meme kanserlerinde sık eksprese edilen bir gendir. Yapılan çalışmalarda özellikle aksiller lenf nodu tutulumu olan hastalarda bağımsız negatif prognostik bir faktör olduğu kabul edilmektedir. Bu çalışmada, 134 meme kanserli kadın hastada C-erbB-2 onkogen ekspresyonu ve diğer prognostik faktörlerle olan ilişkisi araştırılmıştır. C-erbB2 onkogeninin, aksiller lenf nodu metastazı ile ilişkisi gösterilemedi. Ancak aksiller metastatik lenf nodlarında yapışık lenf nodülleri (GATO) oluşumu ile c-erbB2 ekspresyonu arasında istatistik olarak anlamlı bir ilişkili saptandı. Ayrıca çalışmamızda, östrojen reseptörü (ER), progesteron reseptörü (PR), p53, yaş, tümör çapı, metastaz durumu gibi parametreler ile C-erbB-2 arasında anlamlı bir ilişki tespit edilmedi. Tüm bu sonuçlar ile C-erbB-2'nin literatürde de belirtildiği gibi diğer faktörlerden bağımsız bir prognostik faktör olabileceği görüşü desteklenmektedir.

Anahtar Kelimeler:

Meme neoplazmları, Lenf düğümleri, Genler, erbB-2, Onkojen proteinler v-erbB

Is there any relationship between C-ERBB-2 expression and others prognostic factors in breast cancer?

C-erbB-2 gene is frequently over expressed in human breast cancer. Many studies have demonstrated that C-erbB-2 over expression is an independent negative prognostic factor in node-positive breast cancer patients. In this study, C-erbB-2 expression and its relationship with other prognostic factors were investigated in 134 breast cancer patients. The significant relationship between C-erbB-2 and axillary lymph nodes involvement, ER, PR, P53, age, tumor size, metastasis status could not be shown. But statically significant relationship between C-erbB2 over expression and lymph node GATO formation is shown. In a result, C-erbB2 over expression could be a prognostic factor in breast cancer.

Keywords:

Breast Neoplasms, Lymph Nodes, Genes, erbB-2, Oncogene Proteins v-erbB,

PDF

___

1. Parkin DM, Laara E, Muir CS. Estimates of the World wide frequency of sexteen majör cancers in 1980. Int J Cancer 1988; 41: 184-196.
2. Boring CC, Squires TS, Tong T. Cancer statistics 1993. C.A. Cancer J Clin 1993; 43:4-26.
3. Sinvenberg E, Lubera J. Cancer statistics 1987. C.A Cancer J Clin 1987; 37:19.
4. Allred DC, O'Connel P, Fuqua SA, Osborne CK. Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat, 1994; 32:1,13-8.
5. Dawkins HJ, Robbins PD, Smith KLSarna M, Harvey JM, Sternet GF, Papadimitriou JM. What's new breast cancer ? Moleculer perspectives of cancer development ant the role of the oncogene c-erbB2 in prognosis and disease. Pathol Res Pract 1993; 189: 10, 1233-52.
6. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR. Overexpression of the c-erbB2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance ? EurJ Cancer 1992; 28: 2-3, 644-8.
7. Slomon E, Voss R, Hail V et all. Chromosome 5 allele loss in human colorectal carcinomas. Nature 1987, 328:616-620.
8. Drebin JA, Link VC, Greene MJ. Monoclonal antibodies specific for the neu oncogene product directly mediate antitumor effects in vivo. Oncogene 1988; 2:387-394.
9. Schejter ED, Segal D, Glazer L et ali. Altemative 5' exons and tissue specific expression of the Drosophila EGF receptor homologue transcripts. Celi 1986; 46: 1091-1094.
10. Yokota J, Yamamoto T, Toyoshima K et all. Amplifıcation of c-erbB2 oncogene in human adenocarcinornas in vivo. Lancet 1986; 1:765-767.
11. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M. The celi cycle inhibitor 27 is an independent prognostic marker in small (T1a,b)invasive breast carcinoma. Cancer Res 1997; 57: 7, 1259-63.
12. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB2 protein. Cancer 1995; 75: 8, 21: 23-31.
13. O2Mailey FP, Saad Z, Kerkvliet N, Doig G, Stitt L, Ainsworth P, Hundal H, Chambers AF, Turnbull Dİ, Bramwell V. The predictive poWer of semiquantitative immunohistochemical assessment of p53 and c-erbB2 in lymph node-negative breast cancer. Hum Pathol 1996; 27: 9, 955-63.
14. Perin T, Canzonieri V, Massarut S, Bidoli E, Rossi C, Roncadin M, Carbone A. İmmunohistochemical evaluation of multipl biological markers in ductal carcinoma in situ of the breast cancer. Eur J Cancer 1996; 32 A:7: 1148-55.
15. Lagios MD. Ciassification of duct carcinoma in situ (DCIS) with a characterization of high grade lesions: defining cohorts for chemoprevention trıals. J Celi Biochem 1996; Suppl 25: 108-11.
16. Rudas M, Neumayer R, Gnant MF, Mittelböck M, Jakesz R, Reiner A. p53 protein expression, celi proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 1997; 33: 1, 39-44.
17. Ferrero-Pous M, Hacene K, Bouchet C, Le Doussal V, Tubiana-Hulin, Spyratos F. Relationship betWeen c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res. 2000; 6 (12) : 4745-54.
18. Brotherick I, Shenton BK, CoWan WK, Angus B, Home CH, Higgs MJ, Lennard TW. The relationship betWeen flow-cytometric and immunohistochemically detected c-erbB2 expression, grade and DNA ploidy in breast cancer. Cancer Immunol Immunother 1995; 41: 3: 137-45.
19. Ali IU, Campbell G, Lederau R et ali. Lack of evidence for the prognostic significance of c-erbB2 amplification in human breast carcinoma. Oncogene Res. 1988; 3: 1-8.
20. Berger MS, Locher GW, Saurer S et ali. Correlation of c-erbB2 amplification and protein expression in human breast carcinoma With nodal status and nuclear grading. Cancer Res. 1988; 8: 1238-1243.
21. Slamon DJ, Clark GM, Wang SG et ali. Human breast cancer: Correlation of relapse and survival With amplification of the HER-2/ neu gene. Science 1987; 235: 177-182.
22. Aryandono T, Harijadi, Ghozali A. Correlation of clinical, pathological status, hormone receptor avd c-erbB-2 oncoprotein in breast cancer patients. Gan To Kagaku Ryoho 2000; 2: 600-6.